Jane Street Group LLC Sells 24,603 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Jane Street Group LLC cut its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 30.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 54,934 shares of the company's stock after selling 24,603 shares during the period. Jane Street Group LLC owned approximately 0.06% of IDEAYA Biosciences worth $1,412,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in IDYA. Norges Bank bought a new stake in shares of IDEAYA Biosciences during the fourth quarter valued at approximately $13,385,000. FMR LLC boosted its stake in IDEAYA Biosciences by 2.6% during the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock valued at $333,153,000 after purchasing an additional 327,498 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of IDEAYA Biosciences by 5.9% in the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock worth $130,507,000 after purchasing an additional 282,936 shares in the last quarter. WCM Investment Management LLC purchased a new position in shares of IDEAYA Biosciences in the fourth quarter worth $6,030,000. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in shares of IDEAYA Biosciences by 22.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,200,094 shares of the company's stock valued at $30,842,000 after purchasing an additional 220,000 shares in the last quarter. Institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ IDYA traded up $0.14 during midday trading on Friday, hitting $18.82. 1,046,582 shares of the company's stock traded hands, compared to its average volume of 1,003,193. The firm has a fifty day moving average of $17.65 and a 200 day moving average of $21.80. IDEAYA Biosciences, Inc. has a 1 year low of $13.45 and a 1 year high of $44.42. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -5.70 and a beta of 0.26.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the firm earned ($0.53) EPS. On average, equities analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on IDYA. JPMorgan Chase & Co. lifted their price objective on IDEAYA Biosciences from $63.00 to $66.00 and gave the stock an "overweight" rating in a report on Thursday. Stephens reaffirmed an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $54.27.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.